Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2017 | Key findings of the Endeavour study

Evangelos Terpos • 21 Apr 2017
COMy 2017
Multiple Myeloma Bortezomib Carfilzomib Dexamethasone

Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, discusses the Endeavour study (NCT01568866) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. This study compared the progression free survival of dexathasone combined with bortezomib or carfilzomib. The key finding of this study was that dexamethasone plus carfilzomib produced an overall survival advantage, in comparison to dexamethasone plus botezomib.

More from Evangelos Terpos

2:39
Antibody response to COVID-19 vaccine in patients with multiple myeloma and WM
Evangelos Terpos • 10 Dec 2022
2:02
Ocular AEs observed in patients treated with belantamab mafodotin, lenalidomide & dexamethasone
Evangelos Terpos • 10 Dec 2022
1:14
BelaRd: belantamab mafodotin with lenalidomide and dexamethasone in patients with NDMM
Evangelos Terpos • 10 Dec 2022
3:03
The prognostic impact of circulating plasma cells in patients with multiple myeloma
Evangelos Terpos • 10 Dec 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals